Cytek Biosciences, Inc. (CTKB) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cytek Biosciences Reports First Quarter 2023 Financial Results
May 9, 2023 4:05 PM EDTFREMONT, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (Cytek Biosciences or Cytek) (Nasdaq: CTKB) today reported financial results for the first quarter ended March 31, 2023.
First Quarter Highlights
Total revenue was $37.1 million, or $38.1 million on a constant currency basis, representing 6% and 9% increases respectively, over the first quarter of 2022. Organic revenue for Cyteks existing product portfolio was $33.7 million in the first quarter of 2023, representing a decline of 4% compared to the... More